Feb 17, 2024, 15:57
Rami Manochakian: The FDA approves 1st line Osimertinib WITH chemotherapy for advanced EGFRm NSCLC.
Rami Manochakian, Thoracic Oncologist and Hematology-Oncology Fellowship Director at Mayo Clinic, shared on X/Twitter:
“Hot off the press.
The FDA approves 1st line Osimertinib WITH chemotherapy for advanced EGFRm non-small cell Lung Cancer.
Approval based on FLAURA2 trial which showed PFS compared to Osimertinib alone.
HR: 0.62
mPFS: 25.5 vs 16.7 months.”
View additional information.
Source: Rami Manochakian/X